SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is experiencing high volatility amid an intense bidding war for Warner Bros. Discovery, with Paramount's all-cash counter-offer creating uncertainty around Netflix's proposed stock-and-asset deal. The community is sharply divided, with bears foreseeing further declines due to potential debt and regulatory hurdles, while bulls view the stock as deeply oversold and a strong buy ahead of upcoming earnings, anticipating a significant rebound.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending intensely as news circulates about a reported criminal probe into Fed Chair Jerome Powell, which he publicly claims is politically motivated to influence interest rate policy. This unprecedented challenge to the Federal Reserve's independence has sharply divided the community, with many anticipating significant market volatility while others view it as transient political noise that will lead to buying opportunities. Amidst the uncertainty, investors are also closely watching alternative assets like gold, silver, and Bitcoin.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing significant community attention following its showcase of advanced agentic and conversational AI at CES 2026, highlighted by new partnerships with TomTom for automotive and Richtech Robotics for food service, and a Pizza Hut demo. Investors are actively discussing the stock's substantial short interest and the potential for a squeeze, eagerly anticipating upcoming Q4 earnings and further large customer announcements in the expanding voice AI market.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is drawing significant attention amid community discussions surrounding a criminal investigation into Fed Chair Jerome Powell, with many perceiving it as a political threat to central bank independence and a potential catalyst for alternative assets. This market uncertainty, coupled with an upcoming Senate vote on a crypto market structure bill, fuels intense debate between those anticipating a major rally and others predicting further price declines.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

Rich Sparkle Holdings (ANPA) is a major trending topic following its acquisition of a TikTok icon's core company and a substantial private placement. The community is buzzing with comparisons to other highly volatile Hong Kong microcaps, anticipating significant continued movement driven by its low float and ongoing debate over its fundamental valuation versus its speculative potential.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending following strategic deals with nuclear energy companies to power its expanding AI data centers, signaling a long-term commitment to its AI infrastructure. This move is sparking community discussion about the company's significant AI investments and future profitability, even as regulatory scrutiny over acquisitions and supply delays for Ray-Ban smart glasses also remain talking points among investors.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is experiencing a surge in positive sentiment, driven by the successful IPO debut of AI startup MiniMax, where it holds a stake, alongside growing optimism for China's broader AI sector. The community is actively discussing a significant technical breakout, fueled by Alibaba's advancements in AI with its DeepSeek models and speculation around potential access to advanced chips. Many anticipate a substantial move higher for the stock as it shifts from a period of regulatory concern to one highlighting its technological leadership and undervalued position within the evolving Chinese market.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amidst heightened competition in the weight management sector, notably with Amazon Pharmacy now offering GLP-1 medications and the termination of a prior key partnership. This has fueled a sharp divergence in community sentiment, with many expressing significant bearish concerns over the company's market position, while long-term investors view the current valuation as an attractive opportunity given its broader strategy in personalized healthcare and international expansion.

VisionWave Holdings, Inc. engages in the forefront of revolutionizing defense capabilities by integrating advanced artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. The company was founded on March 20, 2024 and is headquartered in Wilmington, DE.

VisionWave Holdings Inc.

VisionWave Holdings, Inc.

VisionWave Holdings is experiencing heightened investor interest driven by recent patent issuances and strategic acquisitions in defense and AI, positioning it as a key player in next-generation autonomous systems. The community is buzzing with comparisons to past parabolic runners, citing the company's low float, significant insider ownership, and recent actions against market manipulation as potential catalysts for a substantial rerating in the defense and AI sector.

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.

Novabay Pharmaceuticals Inc

Novabay Pharmaceuticals (NBY) is experiencing explosive momentum, drawing significant attention as a speculative small-cap play. The community is actively discussing a massive recent price surge, fueled by speculation surrounding a potential pivot to blockchain/crypto assets under new leadership and a perceived short squeeze, though many also warn of its highly speculative nature and potential for a sharp reversal.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know

Viking Therapeutics, Inc. (VKTX) reached $31.99 at the closing of the latest trading day, reflecting a +1.07% change compared to its last close.

VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug

Viking Therapeutics completes enrollment in a phase I maintenance study of VK2735, testing flexible oral and injectable dosing after initial weight loss in obese adults.

Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet

Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Here's How Much $100 Invested In Viking Therapeutics 10 Years Ago Would Be Worth Today

Can the US Launch of NVO's Wegovy Pill Reignite Momentum in 2026?

Novo Nordisk shares jump after the U.S. launch of its FDA-approved Wegovy pill, giving the first oral GLP-1 weight-loss drug a chance to revive 2026 momentum.

Viking Therapeutics (NASDAQ:VKTX) CFO Greg Zante Sells 57,661 Shares

Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) CFO Greg Zante sold 57,661 shares of the company's stock in a transaction on Monday, January 5th. The stock was sold at an average price of...

<ul class="summary-bullets"><li>Regulatory filings showed share sales by Viking’s CEO, CFO and COO on Monday.</li><li>Novo Nordisk announced oral Wegovy pricing starting at $149 a month in the U.S.</li><li>Viking’s lead obesity drug VK2735 is still in Phase 3 clinical trials.</li></ul>Shares of Viking Therapeutics Inc. fell sharply on Monday, logging their worst day in more than four months, after regulatory filings showed significant share sales by the company’s top executives.&nbsp;The stock fell 9.3% to $32.14 in Monday’s regular session before paring some losses with a slight after-hours gain.According to the company’s filings on&nbsp;Monday, Brian Lian, Viking’s president and chief executive officer, sold 233,409 shares, stock worth about $7.7 million. On the same day, Greg Zante, the company’s chief financial officer, sold 57,661 shares valued at roughly $1.9 million, while Marianna Mancini, Viking’s chief operating officer, sold 57,661 shares, also worth about $1.9 million.<h2 class="st-heading-2">Novo’s Wegovy Pricing Adds Competitive Pressure</h2>The insider selling came as investors digested a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-wegovy-pill-price-149-month-retail-tells-shorts-time-to-give-up/cmxMZLwR4bo">major pricing move by Novo Nordisk</a>, which announced that U.S. customers can obtain the oral version of Wegovy starting at $149 per month. Novo said the 1.5 mg and 4 mg doses would be available to self-paying customers at that price beginning Monday, although the cost of the 4 mg dose will rise to $199 per month from April 15. The company added that higher 9 mg and 25 mg doses are priced at $299 per month, with no promotional offers.Novo also said customers with commercial insurance could pay as little as $25 per month for the oral pill. The announcement followed the FDA approval of oral Wegovy, making it the first oral GLP-1 drug approved for weight loss.<h2 class="st-heading-2">Viking’s Obesity Program</h2>Viking's lead obesity candidate, VK2735, is a dual GLP-1/GIP receptor agonist being developed in both subcutaneous and oral formulations. In November, Viking said it finished enrolling patients ahead of schedule in its Phase 3 Vanquish-1 trial, which is testing a once-weekly injection of VK2735 over 78 weeks in about 4,650 adults who are obese or overweight and have at least one weight-related health condition.The primary endpoint of the study is to measure the change in body weight relative to placebo, while also tracking the proportion of patients who achieve 5%, 10%, 15%, and 20% weight loss. Viking is also running a second Phase 3 trial, Vanquish-2, in overweight or obese patients with type 2 diabetes, with enrollment expected to finish in the first quarter of 2026. Earlier Phase 2 results showed patients lost up to 14.7% of their body weight in 13 weeks, which Viking said met its primary and secondary endpoints.<h2 class="st-heading-2">Wall Street Backs Viking</h2>In October, Canaccord initiated coverage of Viking Therapeutics with a ‘Buy’ rating and a $106 price target, calling Viking “a leader in the obesity drug development space.” The firm expects readouts from Viking’s two Phase 3 trials in 2027 and mid-2028, respectively, and pointed to what he described as “strong” Phase 2 efficacy data from the oral version of VK2735 reported in August. He added that Canaccord believes VK2735 could differentiate on “multiple fronts.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Viking was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/vktx_ss_png_ef1044304f.webp" alt="vktx ss.png" width="972" height="147"><figcaption>VKTX sentiment and message volume as of January 5| Source: Stocktwits</figcaption></figure>One user said&nbsp;they would be a “buyer if this comes down to the mid-20s. Already have a position but would love to add more at a discount.”<stembedurl>https://stocktwits.com/T0THEM00NN/message/640902717</stembedurl>Another user pointed out that the insider selling “kills some buyout chances in near future.”<stembedurl>https://stocktwits.com/GreenHawkz/message/640900403</stembedurl><a href="https://stocktwits.com/symbol/VKTX">Viking’s stock</a> has declined 25% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Viking Therapeutics on July 19, 2025. (Photo illustration by Cheng Xin/Getty Images)

Viking Therapeutics Stock Suffers Worst Day In Over 4 Months As Top Execs Dump Shares — Novo’s $149 Wegovy Move Looms

Novo’s pricing applies to lower-dose oral Wegovy, with higher doses set at higher monthly prices.

Equity

Viking Therapeutics (NASDAQ:VKTX) CFO Sells $1,897,046.90 in Stock

Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) CFO Greg Zante sold 57,661 shares of the stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $32.90...

Marianna Mancini Sells 57,661 Shares of Viking Therapeutics (NASDAQ:VKTX) Stock

Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) COO Marianna Mancini sold 57,661 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of...

Insider Selling: Viking Therapeutics (NASDAQ:VKTX) CEO Sells 233,409 Shares of Stock

Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) CEO Brian Lian sold 233,409 shares of Viking Therapeutics stock in a transaction that occurred on Monday, January 5th. The shares were sold...

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

VKTX
Viking Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VKTX News

VKTXViking Therapeutics Inc